Perlingeiro Lab Breakthrough Offers New Hope for Muscular Dystrophy
A groundbreaking new study published in the journal Molecular Therapy heralds a major step forward in treating muscular dystrophies. The research, led by LHI researcher Rita Perlingeiro, PhD, details a clinically-ready process to generate therapeutic cells for muscle regeneration.
Dr. Perlingeiro’s team successfully developed a current good manufacturing practice (cGMP) compliant protocol to create large-scale, cryopreserved PAX7-induced myogenic progenitors (MyoPAXon) from induced pluripotent stem cells (iPSCs). This is a critical development, as it addresses the scalability and safety requirements needed for human clinical trials.
The study, titled "Preclinical quality, safety, and efficacy of a cGMP iPSC-derived myogenic progenitor product for the treatment of muscular dystrophies," demonstrates that MyoPAXon can effectively reconstitute both new muscle fibers and muscle stem cells (satellite cells) in preclinical models. This robust regenerative capacity positions Dr. Perlingeiro's work as a pioneering effort toward the first-ever stem cell-based treatment for devastating muscle-wasting diseases.
